Skip to main content
. Author manuscript; available in PMC: 2013 Apr 9.
Published in final edited form as: Bioconjug Chem. 2009 Jun 24;20(8):1634–1642. doi: 10.1021/bc9001954

Figure 4.

Figure 4

Whole-body SPECT/CT image (A) of 99mTc-RGD-Lys-(Arg11)CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h post-injection; HPLC profile (B) of radioactive urine sample of a B16/F1 murine melanoma-bearing C57 mouse at 2 h post-injection of 99mTc-RGD-Lys-(Arg11)CCMSH. Black arrow indicates the retention time of the original compound of 99mTc-RGD-Lys-(Arg11)CCMSH prior to the tail vein injection.